Patent intelligence · US
US 6770283
DNA expression systems based on alphaviruses
DNA expression systems based on alphaviruses
Patent details — US 6770283
- Jurisdiction
- US
- Status
- expired
- Grant date
- Aug 3, 2004
- Expiration
- Jul 29, 2024
- Applicant
- Bioption AB
- Claims
- 17
- CPC classes
- A61K, A61K39/00
Quick answer
US 6770283 (DNA expression systems based on alphaviruses) is held by Bioption AB. Status: expired. Granted Aug 3, 2004. Expires Jul 29, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Bioption AB
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K39/00
More from Bioption AB
Related pharmaceutical patents in our USPTO index.
-
US 11596610
Compositions in support of health and mental accuity
granted -
US 10117937
Highly branched alpha-D-glucans
granted -
US 9289513
Targeted cytokine for treatment of musculoskeletal diseases
granted -
US 8685932
Targeted transforming growth factor-beta-bound IgG for Treatment of Diseases
granted -
US 6692750
Alphavirus expression vector
expired -
US 6566093
Alphavirus cDNA vectors
expired -
US 6224879
Alphavirus expression vector
expired
Frequently asked questions
What is US patent 6770283?
US 6770283 (DNA expression systems based on alphaviruses) is held by Bioption AB. Status: expired. Granted Aug 3, 2004. Expires Jul 29, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6770283?
Bioption AB is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does US 6770283 expire?
Our index shows an expiration date of Jul 29, 2024 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.